Ardais has appointed Donald Hawthorne president and CEO. He replaces Gregory Phelps, who left Ardais “to pursue other opportunities,” according to Ardais.
Hawthorne, who will also obtain a seat on the company’s board, has been a “contract operating partner” to the health-care venture capital community since 1999. Formerly, he was a partner and CFO at Ampersand Ventures, a private equity firm. Hawthorne holds an MBA from the Stanford Graduate School of Business.
Genetronics Biomedical Corporation has appointed Gene Larson to its board of directors. He is currently chairman and CEO of UST, a medical device company developing high-intensity focused ultrasound for medical applications, and he is a director of Sonotech.
Previously, Larson established and sold Echo Laboratories to Johnson & Johnson, where he continued as a senior executive for five years. He was president of J&J Photomedica, where he was responsible for the development of oncology drug/device technology using photodynamic therapy.
Roche has created a new center called the Roche Biomarker Program and has appointed Tom Metcalfe as its head. The RBP evolved from the company’s Joint Program in Applied Genomics, an initiative designed to “identify and maximize synergies” in the area of genomics within the pharmaceuticals and diagnostics divisions in key disease areas.
The RBP encompasses a “broader vision” including proteomic, metabolic, and genomic approaches to biomarkers to support “all therapeutic areas” being pursued by the Swiss giant.
Metcalfe, for his part, will “operate seamlessly within both [diagnostics and therapeutic] divisions,” said Lee Babiss, vice president of preclinical research and development at Roche. Metcalfe will coordinate the projects and cross-functional workgroups that contributed to the JPAG.
Metcalfe is currently responsible for business development and operational excellence within Roche Molecular Diagnostics. His role in business development will transition to Greg Heath, head of clinical genomics at RMD.